SEC Form 4 · accession 0001209191-15-047699
PHARMACYCLICS INC · PCYC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard van den Broek
Director
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 6:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000949699
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 26, 2015 | U | 29,610 | $261.25 | D | 0 | I | by HSMR Advisors, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.90 | May 26, 2015 | D | 10,000 | D | — | Dec 17, 2019 | Common Stock | 10,000 | 0 | D |
| Stock Option (Right to Buy)F3 | $3.10 | May 26, 2015 | D | 7,258 | D | — | Jan 4, 2020 | Common Stock | 7,258 | 0 | D |
| Stock Option (Right to Buy)F3 | $6.63 | May 26, 2015 | D | 3,619 | D | — | Apr 1, 2020 | Common Stock | 3,619 | 0 | D |
| Stock Option (Right to Buy)F3 | $6.75 | May 26, 2015 | D | 3,555 | D | — | Jul 1, 2020 | Common Stock | 3,555 | 0 | D |
| Stock Option (Right to Buy)F3 | $8.12 | May 26, 2015 | D | 3,139 | D | — | Oct 1, 2020 | Common Stock | 3,139 | 0 | D |
| Stock Option (Right to Buy)F3 | $6.52 | May 26, 2015 | D | 4,140 | D | — | Jan 3, 2021 | Common Stock | 4,140 | 0 | D |
| Stock Option (Right to Buy)F3 | $5.76 | May 26, 2015 | D | 7,500 | D | — | Dec 9, 2020 | Common Stock | 7,500 | 0 | D |
| Stock Option (Right to Buy)F3 | $5.81 | May 26, 2015 | D | 20,000 | D | — | Dec 31, 2020 | Common Stock | 20,000 | 0 | D |
| Stock Option (Right to Buy)F3 | $6.01 | May 26, 2015 | D | 5,240 | D | — | Apr 1, 2021 | Common Stock | 5,240 | 0 | D |
| Stock Option (Right to Buy)F3 | $10.58 | May 26, 2015 | D | 2,976 | D | — | Jul 1, 2021 | Common Stock | 2,976 | 0 | D |
| Stock Option (Right to Buy)F3 | $11.31 | May 26, 2015 | D | 2,784 | D | — | Oct 3, 2021 | Common Stock | 2,784 | 0 | D |
| Stock Option (Right to Buy)F3 | $14.26 | May 26, 2015 | D | 7,500 | D | — | Dec 15, 2021 | Common Stock | 7,500 | 0 | D |
| Stock Option (Right to Buy)F3 | $15.02 | May 26, 2015 | D | 2,409 | D | — | Jan 3, 2022 | Common Stock | 2,409 | 0 | D |
| Stock Option (Right to Buy)F3 | $28.47 | May 26, 2015 | D | 1,052 | D | — | Apr 2, 2022 | Common Stock | 1,052 | 0 | D |
| Stock Option (Right to Buy)F3 | $59.28 | May 26, 2015 | D | 515 | D | — | Jul 2, 2022 | Common Stock | 515 | 0 | D |
| Stock Option (Right to Buy)F3 | $65.56 | May 26, 2015 | D | 510 | D | — | Oct 1, 2022 | Common Stock | 510 | 0 | D |
| Stock Option (Right to Buy)F3 | $49.00 | May 26, 2015 | D | 7,500 | D | — | Nov 9, 2022 | Common Stock | 7,500 | 0 | D |
| Stock Option (Right to Buy)F3 | $61.44 | May 26, 2015 | D | 546 | D | — | Jan 2, 2023 | Common Stock | 546 | 0 | D |
| Stock Option (Right to Buy)F3 | $79.67 | May 26, 2015 | D | 343 | D | — | Apr 1, 2023 | Common Stock | 343 | 0 | D |
| Stock Option (Right to Buy)F3 | $74.48 | May 26, 2015 | D | 3,750 | D | — | May 9, 2023 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F3 | $85.39 | May 26, 2015 | D | 374 | D | — | Jul 1, 2023 | Common Stock | 374 | 0 | D |
| Stock Option (Right to Buy)F3 | $139.89 | May 26, 2015 | D | 226 | D | — | Oct 1, 2023 | Common Stock | 226 | 0 | D |
| Stock Option (Right to Buy)F3 | $108.44 | May 26, 2015 | D | 264 | D | — | Jan 2, 2024 | Common Stock | 264 | 0 | D |
| Stock Option (Right to Buy)F3 | $107.42 | May 26, 2015 | D | 280 | D | — | Apr 1, 2024 | Common Stock | 280 | 0 | D |
| Stock Option (Right to Buy)F3 | $95.08 | May 26, 2015 | D | 3,750 | D | — | May 9, 2024 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F3 | $89.58 | May 26, 2015 | D | 456 | D | — | Jul 1, 2024 | Common Stock | 456 | 0 | D |
| Stock Option (Right to Buy)F3 | $115.80 | May 26, 2015 | D | 338 | D | — | Oct 1, 2024 | Common Stock | 338 | 0 | D |
| Stock Option (Right to Buy)F3 | $124.46 | May 26, 2015 | D | 318 | D | — | Jan 2, 2025 | Common Stock | 318 | 0 | D |
| Stock Option (Right to Buy)F3 | $257.015 | May 26, 2015 | D | 180 | D | — | Apr 7, 2025 | Common Stock | 180 | 0 | D |
Explanation of responses
- F1Price reflects aggregate per share consideration paid pursuant to the Tender Offer.
- F2Mr. van den Broek is the managing partner of HSMR Advisors, LLC.
- F3Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.